Novogene revolutionizes their genomic sequencing services with the acquisition of the PacBio Revio™ system for more accurate and affordable long-read sequencing.

Novogene, a leading global provider of sequencing services, has announced the introduction of services on PacBio’s latest Revio platform. The new platform is a game-changer in long-read sequencing, allowing for more accurate and affordable comprehensive variants profiling and direct methylation detection, with implications for research in a wide range of fields, including agrigenomics, human genetics, and cancer research.

With a 15x increase in throughput over its predecessor-Sequel IIe, PacBio’s Revio system can generate 1,300 human genome equivalents per year. It also promises an exceptional accuracy rate of 90% for bases ≥ Q30 and a median read accuracy ≥ Q30, while capturing a comprehensive snapshot of genetic variants (including SNVs, InDels, structural variants, tandem repeat expansions) in a single sequencing run.

With 18 patents, 40 software copyrights, and a cumulative impact factor of over 1,100 in top-tier international journals, Novogene has established a significant influence in the long-read sequencing field and has developed expertise in variation calling, genome assembly and gene annotation.

Novogene is committed to improving its service level and providing customers worldwide with more accurate and efficient service experiences. The strong expertise and profound background in genetic technology make Novogene a trusted partner for genome research worldwide. With the introduction of the PacBio Revio platform, Novogene continues to lead the trend of genome research worldwide and provide increasingly comprehensive solutions for scientists.

To find out more about our long-read sequencing services, contact us here.